Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.
Aids Research And Therapy
Stirrup, Oliver T OT; Dunn, David T DT; Tostevin, Anna A; Sabin, Caroline A CA; Pozniak, Anton A; Asboe, David D; Cox, Alison A; Orkin, Chloe C; Martin, Fabiola F; Cane, Patricia P; , ; ,
A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity.
Plos One
Wright, David W DW; Deuzing, Ilona P IP; Flandre, Philippe P; van den Eede, Peter P; Govaert, Micheline M; Setiawan, Laurentia L; Coveney, Peter V PV; Marcelin, Anne-Geneviève AG; Calvez, Vincent V; Boucher, Charles A B CA; Beerens, Nancy N
Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis.
Bmc Infectious Diseases
Rath, Barbara A BA; von Kleist, Max M; Castillo, Maria E ME; Kolevic, Lenka L; Caballero, Patricia P; Soto-Castellares, Giselle G; Amedee, Angela M AM; Robinson, James E JE; Katzenstein, David K DK; Van Dyke, Russell B RB; Oberhelman, Richard A RA
Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand.
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.
Plos One
Stoddart, Cheryl A CA; Joshi, Pheroze P; Sloan, Barbara B; Bare, Jennifer C JC; Smith, Philip C PC; Allaway, Graham P GP; Wild, Carl T CT; Martin, David E DE
Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
Antimicrobial Agents And Chemotherapy
Masquelier, Bernard B; Breilh, Dominique D; Neau, Didier D; Lawson-Ayayi, Sylvie S; Lavignolle, Valérie V; Ragnaud, Jean-Marie JM; Dupon, Michel M; Morlat, Philippe P; Dabis, F F; Fleury, H H; ,